Showing results (201-210 of 226) with videos related to
Sort By:
Pageof 23
World Journal of Stem Cells|April 12, 2017
Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapyJorge Zorzopulos, Steven M Opal, Andrés Hernando-Insúa, et al.Critical Care Medicine|February 6, 2004
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trialSteven Opal, Pierre-Francois Laterre, Edward Abraham, et al.JAMA|October 3, 2019
Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical TrialPierre-Francois Laterre, Scott M Berry, Allan Blemings, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2003
Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated)Steven M Opal, Gary E Garber, Steven P LaRosa, et al.The Journal of Infectious Diseases|October 12, 2014
CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitisGirish Ramachandran, Raymond Kaempfer, Chun-Shiang Chung, et al.Journal of Critical Care|December 11, 2025
Survival after ICU discharge is shaped more by chronic disease than admission severityAlice Blet, Anouk Walter-Petrich, Ményssa Chérifa, et al.Kidney International|August 14, 2020
SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubuleAlexis Werion, Leila Belkhir, Marie Perrot, et al.American Journal of Respiratory and Critical Care Medicine|February 8, 2011
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trialRichard G Wunderink, Pierre-François Laterre, Bruno Francois, et al.Shock (Augusta, Ga.)|January 26, 2011
A monoclonal antibody against RAGE alters gene expression and is protective in experimental models of sepsis and pneumococcal pneumoniaEirini Christaki, Steven M Opal, James C Keith, et al.Annals of the American Thoracic Society|February 2, 2018
Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical TrialRoger J Lewis, Derek C Angus, Pierre-François Laterre, et al.Pageof 23